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Abstract
Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal
surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied
mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating
agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized
that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting
local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of
Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant
mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic
degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production
of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1
transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety
profile suggests promise as an HIV-1 mucosal vaccine formulating agent.
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Introduction
Despite increasing access to antiretroviral drugs in developing
countries, prevention or reduction of HIV-1 sexual transmission is
needed to contain the continuing growth of the pandemic [1]. One
of the most effective preventive strategies against many infectious
diseases is prophylactic vaccination. However, an efficaceous HIV-
1 vaccine remains unavailable. A major element of HIV-1 vaccine
design is the induction of neutralizing antibodies by immunization
with recombinant HIV-1 envelope glycoproteins (Env) or
engineered fragments thereof [2,3]. Since HIV-1 is transmitted
predominantly sexually, the most appropriate site to elicit an
antibody barrier is at the genital mucous membranes [4,5]. At
present, we do not know how to induce long-term mucosal
immunity against HIV-1 by conventional immunization strategies,
and obtaining high antibody titres at mucosal surfaces appears to
be regulated by mechanisms distinct from the systemic immune
system [6,7]. Thus the induction of long-lived mucosal immunity
may require vaccine administration directly to the mucosae,
especially if the efficient induction of antigen-specific IgA secretion
is required [8]. However, HIV-1 Env-based antigens generally
lack robust intrinsic immunogenicity, and there are no licensed
mucosal adjuvants currently available. Moreover, caution must be
exercised when considering the use of adjuvants in a mucosal
context, since mucosal application of an adjuvant-containing
formulation may induce local inflammation, potentially increasing
the HIV-1 transmission risk by recruitment of activated CD4+ T
cells that are the primary targets for HIV-1 replication in vivo
[9,10,11]. Thus adjuvants for mucosal HIV-1 immunization
would ideally promote immune responses whilst maintaining a
non-inflammatory environment.
In the absence of a vaccine, another strategy currently under
development to reduce HIV-1 transmission is the use of topical
microbicides [12]. PRO 2000 is an anionic polymer that was
under investigation as a candidate microbicide, but was recently
demonstrated to be ineffective at preventing HIV-1 transmission
[13]. However, PRO 2000 has an excellent safety record for
vaginal application with no evidence for local toxicity or irritation
[14,15,16] and has been demonstrated to suppress the generation
of vaginal inflammatory mediators in women [17]. Moreover,
being a gel PRO 2000 has a relatively long residency time in the
vaginal tract [16]. For these reasons, PRO 2000 might be a useful
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An additional point is that similar to other polyanions [18,19]
PRO 2000 reversibly binds viral HIV-1 gp120 [20], and therefore
may interact with soluble recombinant Env-based candidate
vaccine antigens, modifying their antigenicity. Polyanion binding
to gp120 selectively and reversibly masks antigenic surfaces
containing positive charges, including the V3 loop and the CD4-
induced (CD4i)-surface [18,19]. Most of the V3 loop is considered
too variable to be helpful as a broadly-specific neutralization target
[21] and CD4i epitopes are poorly accessible to antibody on the
intact viral spike and hence are poor neutralizing antibody targets
[22]. We therefore hypothesized that the formation of reversible
gp140-PRO 2000 complexes in a vaccine formulation might
improve the antigenicity of gp140 by re-directing immune
responses towards more conserved neutralization-relevant surfac-
es, and might additionally act as a depot, increasing antigen
residency time and thereby immunogenicity. Since basic amino
acids form the cleavage sites of most proteases [23], we also
hypothesized that complexing of Env with a polyanion might
protect the glycoprotein from proteolytic digestion, further
enhancing the residency time of intact antigen at the mucosal
surfaces. This would be of particular importance for a glycoprotein
such as HIV-1 gp120, in which many of the conserved
neutralization epitopes are highly conformational and discontin-
uous [24,25].
Here we present proof of principle that co-formulation of a
recombinant trimeric gp140 derived from a clade B/C HIV-1
isolate with the polyanion PRO 2000 results in favourably
modified antigenicity, increased immunogenicity, and unexpect-
edly, reduced mucosal inflammatory responses as a result of TLR4
antagonism. We thus conclude that PRO 2000 may be a useful
formulation agent for vaginal vaccine delivery.
Results
Immunogenicity of vaginally-applied gp140-PRO 2000
complexes in mice
Trimeric forms of HIV-1 Env may be superior at inducing
neutralizing antibody responses [26,27,28], and Clade C dominates
the worldwide HIV-1 pandemic [29]. We therefore used a soluble
trimeric form of HIV-1 Env, comprising the membrane external
Env sequence (gp140) from clade B/C recombinant CCR5-tropic
(R5) Chinese viral isolate 96CN54, as antigen, here termed
gp140CN54. This antigen was produced to good manufacturing
practice standards, and contained undetectable levels of endotoxin
contamination. Antigenicity and trimericity were assessed by
surface plasmon resonance (SPR)-analysis and blue native PAGE,
respectively. The antigen bound several conformation-dependent
ligands including soluble CD4 (sCD4) and the neutralizing
monoclonal antibody (NmAb) IgG1b12 [30,31] (b12), and mAb
binding to the CD4-induced (CD4i) surface was increased after
sCD4 binding (Figure S1). Taken together these data suggest that
the antigen adopts a properly-folded conformation with presenta-
tion of at least one well-conserved neutralizing epitope.
The vagina is generally considered to be poor site for immune
induction [32], suggesting that the administration of an antigen in
the absence of adjuvant is unlikely to elicit robust adaptive
immune responses, and indeed may drive a tolerogenic response
[33]. To test whether PRO 2000 modulated the immunogenicity
of vaginally-applied Env antigen, two groups of mice were
immunized intravaginally four times with 12.5 mg gp140CN54 in
control gel alone, or in control gel supplemented with 1% PRO
2000. The PRO 2000 used here was confirmed to have ,0.05 U/
mL endotoxin. Analysis of vaginal lavage revealed that only the
group receiving gp140 in PRO 2000 gel, but not antigen alone,
elicited vaginal IgA responses significantly higher than the pre-
immune samples (Figure 1A). The gp140-specific IgA responses
elicited by administration of gp140 in PRO 2000 were stable
between the time of the final boost at day 59 until the end of the
experiment at day 210, implying unexpectedly good durability of
these responses. At day 210, endpoint IgA titres were approxi-
mately 5-fold higher in the antigen + PRO 200 group than the
group receiving antigen alone. Furthermore, when the two groups
were directly compared by collectively analyzing all time points
after the first immunization, a significant difference was found
(p=0.0286, Mann Whitney test). Vaginal IgG titres were
significantly increased above baseline in the animals receiving
antigen alone at only one time point, but were significantly
increased at three time points in mice receiving gp140 in PRO
2000 (Figure 1B), although titres were relatively low and waned
rapidly. When vaginal IgG titres of both groups were directly
compared by collectively analyzing all time points after the first
immunization no significant difference was found. Furthermore we
were unable to detect any systemic responses in serum (data not
shown). Taken together, these data indicate that PRO 2000
predominantly enhances compartmentalized mucosal IgA re-
sponses in mice.
Immunogenicity of vaginally-applied gp140-PRO 2000
complexes in rabbits
To evaluate the immunomodulatory activity of PRO 2000 in a
second species, we immunized rabbits intravaginally with antigen
formulated in carrier gel alone or in PRO 2000 gel. We observed
significant increases in systemic and vaginal IgG responses in the
presence of PRO 2000 in rabbits after the second series of boosts
(Figure 2A–B). Assay of vaginal lavage for antigen-specific IgA
revealed increases compared to the pre-immune sera, but
statistically equivalent titres in both gp140 alone and gp140-
PRO 2000 groups, indicating that in this species PRO 2000 did
not significantly increase IgA responses (Figure 2C). To test
whether vaginal immunization induced neutralizing activity at the
vaginal mucosa, week 12 rabbit vaginal lavage samples were
analyzed in a pseudovirus neutralization assay. Significant
neutralization of a sensitive tier 1 heterologous clade C
pseudovirus (MW965) [34] was observed for both groups
(Wilcoxon signed rank test p=0.0313, respectively), and the
gp140 + PRO 2000-immunized rabbits showed significantly
increased neutralization compared to the gp140 alone group
(Figure 2D, p=0.0278, unpaired t-test). Limited yields of vaginal
lavage unfortunately precluded further analysis of neutralization
activity with env from other viral clones. The increased
neutralization capacity might also be mediated by a PRO 2000-
induced secretion of antiviral mediators or immunoglobulins,
however a recent clinical study has shown that PRO 2000
dampened immune mediator secretion rather than inducing it
[17]. The vaginal and systemic IgG titres correlated significantly
with each other (Figure S2C) and with the neutralization capacity
of the vaginal lavage samples (Figure 2E), whereas total vaginal
immunoglobulin levels were indistinguishable between study
groups (Figure S2A–B). This strongly suggests that neutralization
was due to the local immunization-elicited antibody responses of
the rabbits.
Second-site adjuvantation of antigen + PRO 2000
formulations
To attempt to further increase immune responses to vaginal Env
immunization, we combined the antigen-PRO 2000 delivery with
Mucosal Anti-Inflammatory HIV-1 Vaccine
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accepted as a good inducer of immunity at the vaginal mucosa
[35,36,37]. As nasal immunizations are less likely to trigger genital
mucosal inflammation and are therefore not associated with an
increased risk of genital HIV-1 transmission, we used a more
potent adjuvant for immunizations via the intranasal route. This
mucosal priming adjuvant was a polycation-based agent (Figure 3)
[38,39] which has intrinsic adjuvant activity and induces a
balanced Th response (our unpublished data). By contrast with
the previous experiment, mice receiving the prime and three
vaginal immunizations had readily detectable gp140-specific
serum and vaginal IgG responses, which were significantly higher
in the gp140 + PRO 2000-boosted group than the gp140 alone
group (Figure 3A–B, p=0.0195 and 0.0305 respectively, unpaired
t-tests). Moreover, vaginal IgA responses were 3-fold increased in
the gp140 + PRO 2000 group compared to gp140 alone
(Figure 3C), although this trend did not reach significance. Thus
mucosal priming at a second site with a heterologous adjuvant
resulted in enhanced local and systemic antibody responses.
PRO 2000 induces a T helper cell type-2 (Th2) immune
bias
Recently it has been demonstrated that the recruitment of viral
target cells, predominantly T helper type-1 (Th1)-activated CD4
+
T cells, to the primary focus of mucosal HIV-1 replication is an
important factor influencing the outcome of vaginal lentiviral
infection [11]. Since both Th1 bias and T cell recruitment are
primarily driven by a pro-inflammatory environment, we wished
to determine whether PRO 2000 influenced the mucosal Th bias.
The IgG1/IgG2a ratio is indicative of a Th2/Th1 adaptive
immune bias. Analysis of the antigen-specific IgG1/IgG2a ratio in
the serum samples reported on in Figure 3 revealed that mice
boosted with the gp140 + PRO 2000 combination had a
significantly greater IgG1/IgG2a ratio than those boosted with
gp140 alone (Figure 4A p=0.0055, Mann Whitney test), implying
a Th2-biased response. To further investigate the Th2-biasing
activity of PRO 2000, gp140 + PRO 2000 or gp140 alone were
administered subcutaneously in Freund’s Complete Adjuvant
(FCA), a well-characterized and potent Th1-adjuvant [40]. Serum
samples showed statistically indistinguishable gp140-specific IgG1
responses (Figure 4B), but significantly reduced IgG2a titres
(Figure 4C, p=0.0181, unpaired t-test) and significantly increased
IgG1/IgG2a titre ratios (Figure 4D, p=0.0379, Mann Whitney
test) for animals receiving gp140 + PRO 2000 in FCA.
Confirmation of a PRO 2000-induced local Th2 bias came from
analysis of T cell cytokine profiles. Cells derived from the vagina-
draining inguinal lymph nodes of vaginally-immunized mice (from
the experiment shown in Figure 3) were cultured in gp140 and
supernatants were analyzed by a multiplex cytokine/chemokine
assay on days 1 and 3. Significantly increased levels of the Th2-
cytokine IL-4 but decreased levels of pro-inflammatory cytokines
TNF-a and IL-1 a were observed in mice immunized with gp140
+ PRO 2000 (Figure 5A-C), diagnostic of a Th2 bias and
demonstrating the anti-inflammatory activity of PRO 2000.
Moreover, the chemokine CCL2 (MCP-1) was significantly
decreased in cultures from gp140 + PRO 2000 immunized
animals (Figure 5D). CCL2 has been shown to increase HIV-1
entry into resting CD4
+ T cells [41] and trigger recruitment of
HIV-1-susceptible target cells [42]. Thus reduced CCL2-secretion
might defavour HIV-1 replication within the vaginal mucosa.
PRO 2000 interferes with TLR4-signalling
One mechanism for inducing a Th2-biased immune response
might be for PRO 2000 to antagonize a default vaginal Th1
environment brought about by resident bacterial flora. PRO 2000
is structurally related to dextran sulfate, which has recently been
shown to inhibit TLR4-induced maturation of dendritic cells by an
unknown mechanism [43]. We therefore investigated whether
PRO 2000 influenced the Th bias by interfering with TLR4-
mediated signalling. We stimulated a murine TLR reporter cell
line with ultra-pure S. minnesota LPS in the absence or presence of
PRO 2000. LPS stimulation of the cells was blocked by PRO 2000
in a dose-dependent manner (Figure 6A), whereas Pam3CSK4 (a
TLR2 agonist)-mediated stimulation of the same cell line was
unaffected by PRO 2000 (Figure 6B). To evaluate whether PRO
2000 might directly bind TLR4 and block LPS binding, we used
SPR to quantify PRO 2000 interactions with the LPS-binding
complex of TLR4 and MD-2. PRO 2000 interacted strongly with
immobilized human TLR4:MD-2 (Figure 6C). Since LPS interacts
with TLR4:MD-2 via its lipid A moiety, we analyzed whether
PRO 2000 bound specifically to the lipid A interaction site on the
TLR4:MD-2-complex. Soluble TLR4:MD-2 with or without
Figure 1. PRO 2000 co-application induces increased mucosal antibody responses in mice. BALB/c mice (n=7) were immunized four
times vaginally with 12.5 mg gp140 +/2 1% PRO 2000; Time courses of the vaginal lavage IgA (A) and IgG (B) endpoint titres. gp140 + PRO indicates
combined gp140 and PRO 2000. Titre data were log-transformed and are shown as mean 6 SEM. The grey dashed line indicates the ELISA detection
limit. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0015861.g001
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molar ratios. We confirmed previous observations that soluble
TLR4:MD-2 directly interacts with immobilized lipid A, whereas
PRO 2000 showed no detectable lipid A binding (Figure 6D). The
lipid A-TLR4:MD-2 interaction was inhibited in a dose-depen-
dent manner when PRO 2000 was co-injected, and was abolished
by a 10-fold molar excess of PRO 2000. These data demonstrate
that PRO 2000 binds TLR4:MD-2, thereby inhibiting LPS-
engagement of the receptor.
Antigenicity and stability of gp140-PRO 2000 complexes
A previous study has reported reversible interactions between
HIV-1 gp120 derived from the MN and YU2 isolates and PRO
2000 [20]. Since such interactions may transiently alter antige-
Figure 2. PRO 2000 co-application induces increased systemic and mucosal antibody responses in rabbits. New Zealand White rabbits
(n=6) received six vaginal immunizations using 50 mg antigen per dose in the presence or absence of 1% PRO 2000. (A) Time course of rabbit serum
IgG endpoint titres. (B) Endpoint IgG titres of week 12 vaginal lavage samples. (C) Endpoint IgA titres of week 12 vaginal lavage samples. (D) MW965
pseudovirus neutralization of week 12 vaginal lavage samples. Horizontal bars represent geometric means. Samples were tested at 1:8 dilution; 100%
infection level was defined by pre-immune samples. (E) Correlation of the rabbit serum- and vaginal gp140-specific IgG responses with the MW965
pseudovirus neutralization (D) of week 12 samples. Red symbols represent data from animals immunized with gp140 + PRO 2000. Pre-immune
indicates samples collected prior to the first immunization; gp140 + PRO indicates combined gp140 and PRO 2000. Titre data were log-transformed
and are shown as mean 6 SEM. The grey dashed line indicates the ELISA detection limit. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0015861.g002
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surfaces, we tested whether PRO 2000 interacts with gp140CN54
using SPR. PRO 2000 was flowed over immobilized gp140CN54
and revealed rapid binding with a slow dissociation rate
(Figure 7A). To probe binding specificity we analyzed interference
by PRO 2000 with the binding of mAbs of known epitope
specificity to gp140 (Figure 7B). MAbs specific for the CD4i
surface (E51, X5) and the V3 loop (19b) were potently inhibited,
coordinate with the concept that polyanions bind these surfaces
[18,19]. By contrast, the epitope of the broadly neutralizing mAb
b12 was not obscured by PRO 2000 but became modestly (,40%)
more exposed after PRO 2000 binding (Figure 7B) which may
favour induction of antibodies of this specificity.
Since most proteases recognize sequences containing basic
amino acids, and since PRO 2000 binds positively charged
surfaces, we hypothesize that PRO 2000 might mask proteolytic
cleavage sites and protect the antigen from degradation. To test
the hypothesis we monitored antigen degradation in human
vaginal lavage by Western blot (Figure 7C–D). In the absence of
PRO 2000, gp140 was rapidly degraded into peptide fragments
with a half-life of about 2 h, whereas in the presence of PRO 2000
the half-life was significantly extended to approximately 24 h.
Figure 3. Second-site immunization in the presence of PRO 2000 increases systemic and mucosal antibody responses. BALB/c mice
(n=7) were primed intranasally with 10 mg gp140 per animal in polycation and were boosted three times vaginally with gp140 +/2 PRO 2000.
Samples were collected 14 days after the final vaginal immunization. Serum IgG endpoint titres (A), or vaginal lavage IgG (B) and IgA (C) endpoint
titres normalized to the total IgG or IgA content or each sample, respectively, are displayed. gp140 + PRO, combination of gp140 and PRO 2000.
* p,0.05.
doi:10.1371/journal.pone.0015861.g003
Figure 4. Influence of PRO 2000 co-administration on the type of T helper cell response. The serum specific IgG1- and IgG2a titres were
determined as indicators of a Th2 or Th1 type of response, respectively. (A) Serum IgG1/IgG2a endpoint titre ratios of vaginally immunized mice
(described in Figure 3A–C). (B–D) BALB/c mice (n=7) were primed s.c. with gp140 +/2 PRO 2000 in FCA and were boosted using the same route and
formulation without FCA. (B) Serum IgG1 endpoint titres; (C) IgG2a endpoint titres; (D) IgG1/IgG2a endpoint titre ratio. gp + PRO, combination of
gp140 and PRO 2000. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0015861.g004
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from proteolytic degradation, thereby potentially increasing its
residency time at mucosal surfaces.
Discussion
The small animal vaginal immunization models described here
provide proof-of-principle for two important concepts: 1) that
vaginally-applied PRO 2000, a gel that is well-tolerated in a
human vaginal context, can act as a B cell adjuvant to increase and
sustain both local and systemic specific antibody responses; 2) that
PRO 2000 is a TLR4 antagonist that reduces mucosal pro-
inflammatory responses and so drives a Th2 immune bias. Further
observations of potential benefit relate to the selective antigenic
masking of gp140 epitopes that may lead to enhanced generation
of more conserved antibody responses and protection of gp140
from proteolytic degradation leading to increased mucosal
residency time.
The finding that gp140 formulated in PRO 2000 elicited
specific mucosal and systemic B and T cell responses was
encouraging since the vaginal mucosa has been considered a
difficult site for induction of adaptive immunity [32,33]. However,
a more recent analysis has suggested that the rabbit vaginal vault
may be an immune inductive site when very high doses of antigen
are applied on a frequent basis [44]. Although our experiments
were not specifically designed to evaluate the duration of the
mucosal immune response to vaginal immunization, we neverthe-
less observed that mice immunized with antigen in PRO 2000
maintain specific IgA responses for up to 150 days after the last
boost. Despite the relatively modest titres, this is promising as it
suggests induction of long-lived local plasma cells that escape
tolerogenic suppressive mechanisms. In rabbits, we observed the
induction of equivalent IgA responses in presence or absence of
PRO 2000 but significantly increased vaginal and systemic IgG in
animals receiving gp140 in PRO 2000. This confirms the
immunostimulatory activity of PRO 2000 in a second species,
but indicates that the type of antibody response is species-specific.
The observation that specific serum IgG and vaginal IgG titres
correlate with each other and with the pseudovirus neutralizing
capacity of vaginal lavage samples supports the notion that vaginal
IgG is primarily derived from serum transudate [45,46]. The
neutralizing antibody titres demonstrated here were against a
heterologous clade C Env-pseudotyped virus, demonstrating some
breadth of activity. We acknowledge that titres were low and this
pseudovirus Env is unusually sensitive to neutralization [47],
but this result should encourage further development of this
immunization concept with the use of next-generation Env-based
antigens as they become available. Induction of antigen-specific
IgG and IgA at the vaginal mucosa was modest, but encouragingly
intranasal priming with experimental adjuvant prior to boosting
with gp140-PRO 2000 further increased antibody responses.
Although the mucosal antigen-specific antibody responses that we
observe are of relatively low titre, they may be further optimized
by increasing antigen dose, increasing the number of boosts, or
adding a heterologous adjuvant prime as demonstrated in figure 3.
Moreover, a recent study demonstrated that lower than previously
Figure 5. Immunomodulary activity of PRO 2000. Mononuclear cells derived from the vagina-draining Inguinal lymph nodes of vaginally
immunized mice (described in Figure 3A–C) were cultured in the presence of 15 mg/ml of gp140, and the concentrations of cytokines/chemokines in
supernatants were quantified on day 1 and 3 of the culture by multiplex assay. (A) IL-4, (B) TNF-a,( C) IL-1a,( D) CCL2. Results for individual mice are
displayed. gp, gp140; PRO, combination of gp140 and PRO 2000. * p,0.05.
doi:10.1371/journal.pone.0015861.g005
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reduce transmission in a low-dose challenge model, and that
antibody effector functions may play a role distinct from, or
additional to, neutralization [48].
The finding that PRO 2000 drives an anti-inflammatory Th2-
biased environment is of interest because of the potential risks of
local inflammation resulting in increased susceptibility to HIV-1
infection. A pro-inflammatory environment may lead to local
tissue damage, and may result in recruitment of HIV-1-
susceptible target cells to the mucosae [11]. Furthermore,
CCL2 may increase HIV-1 entry into resting CD4
+ T cells
[41] and triggers recruitment of HIV-1-susceptible target cells
[42]. Thus reduced CCL2-secretion might defavour HIV-1
infection of the vaginal mucosa in vivo. We hypothesized that
PRO 2000 might shift the immune response towards a Th2-type
by inhibiting the local Th1 homeostasis probably induced by
bacterial microflora. Indeed we found that PRO 2000 compet-
itively inhibited the interaction between bacterial LPS and its
cognate receptor TLR4, a potent inducer of Th1-type immune
responses. Interestingly, PRO 2000 has recently been shown to
block the LPS-induced cytokine response of human dendritic cells
[49], which supports our finding. This result is consistent with the
cellular cytokine profile we found in mice immunized in the
presence of PRO 2000, since TNF-a and IL-1a are produced
after LPS stimulation. The probable source of vaginal LPS is the
local bacterial flora. Accordingly, lavage from women with
bacterial vaginosis, an imbalance of naturally occurring bacterial
flora, showed increased TNF-a secretion and TLR4 mRNA
expression [50], illustrating the capacity of these flora to trigger
immune responses.
These results, together with the ability of PRO 2000 to preserve
antigen integrity in a vaginal environment and previously-
published evidence that vaginally-applied PRO 2000 is safe in
clinical trials with no evidence for local toxicity and good vaginal
retention [14,15,16], make a case for further exploration of PRO
2000 as a topical vaccine formulation agent. Although PRO 2000
has failed to prevent sexual HIV-1 transmission in a phase-III
clinical trial [51], our data support further exploration of its
potential use as a mucosal vaccine-formulating agent capable of
promoting antigen-specific immune responses whilst inhibiting
local inflammation. This vaginal vaccine concept might also
provide an ideal platform for the incorporation of next-generation
microbicides, such as antiretroviral drugs, which would combine
potential long-term protection offered by frequently-boosted
mucosal antibody responses with short-term protection offered
by microbicide use.
Methods
Ethics statement
All animal studies were performed in accordance with UK
national guidelines (Animals (Scientific Procedures) Act 1986) and
were authorized by the UK Home Office and the Oxford local
institutional ethical review board (Project license no. 30/2390).
Figure 6. PRO 2000 inhibits LPS signalling and inhibits the TLR4-MD2-lipid A interaction. Murine embryonic fibroblast (MEF) TLR reporter
cells were activated with ultra-pure LPS (A, corresponding legend in B) or with the synthetic TLR2 agonist Pam3CSK4 (B) in the presence of 10, 30 or
90 mM PRO 2000 or in medium alone. Means of triplicates 6 SD are shown. For surface plasmon resonance binding assays (C–D), TLR4:MD2-
complexes were immobilized on a CM5 chip (C), and binding of 100 mM PRO 2000 or low molecular weight dextran was observed, or lipid A was
immobilized on a HPA chip (D) and binding of 155 nM TLR4:MD2, 1.54 mM or 77 nM PRO 2000 or combinations thereof were observed.
doi:10.1371/journal.pone.0015861.g006
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Trimeric gp140 was derived from HIV-197CN54, a chinese clade
B/C recombinant, CCR-5 tropic (R5) isolate (Accession no.
AX149771). The near full-length clone p97CN54 was obtained
originally from HIV isolated from a Chinese patient [52,53] and
was made available by H. Wolf and R. Wagner, University of
Regensburg, Germany. Trimeric clade C gp140 (gp140CN54) was
produced as a recombinant product in CHO cells and
manufactured to GMP specification by Polymun Scientific,
Vienna, Austria.
Animals and immunizations
6–12 weeks old female BALB/c mice were used for the mouse
immunogenicity studies. Intranasal immunizations were adju-
vanted with polycation (Sigma-Aldrich, Gillingham, UK). Intra-
vaginal immunizations were carried out by injecting 20 mlo f
antigen and/or 1% PRO 2000 (Indevus, now Endo Pharmaceu-
ticals, Newark, DE) formulated in carrier gel into the vagina of the
mice. The murine oestrous cycle was synchronized by injecting
1.5 mg of water-soluble progesterone (Sigma-Aldrich) per mouse
three days prior to vaginal immunization. For subcutaneous
immunizations, 0.1 ml of a 1:1 mixture of antigen in PBS and
FCA (Sigma-Aldrich) was injected into the flank of the mice. A
subsequent subcutaneous boost immunization was performed
without adjuvant in week 3 and serum samples were collected in
week 5. Vaginal lavage samples were collected not sooner than 1
week after vaginal immunization by pipetting 2650 ml of sterile
PBS in and out of the vagina several times using sterile blunted
micropipette tips.
For rabbit experiments, 8–10 weeks old female New Zealand
Whites were used. All rabbits received a total of six intavaginal
immunizations with 200 ml 5% hydroxyethylcellulose (HEC) gel
containing 50 mg gp140 and/or 1% PRO 2000. Groups of 3
rabbits per experimental arm received an intranasal prime
immunization in week 0 with 500 mg poly(I:C) and 50 mg
gp140CN54 in 100 ml saline or with 500 mg poly(I:C) in 100 ml
saline alone. Antibody titres between these subgroups were not
statistically different at any time point of the experiment, therefore
the intranasal prime was assumed to be ineffective in rabbits and
results were pooled. Vaginal lavage samples were collected one
week after vaginal immunization by injecting and withdrawing
0.5 ml of sterile PBS several times using a sterile catheter. The
optimal gp140CN54 antigen dose to differentiate between adju-
vanted versus non-adjuvanted mucosal immunization was deter-
mined empirically in previous experiments.
Neutralization assays
Neutralization of clade C MW965 pseudovirus was assessed in a
modified pseudovirus neutralization assay described previously
[54]. Rabbit vaginal lavage samples collected prior to immuniza-
tion (pre-immune samples) and week 12 after 6 intravaginal
immunizations were tested at 1:8 dilution. The mean infec-
tion level observed with pre-immune samples was used as the
100% infection level, and the relative neutralization of week 12
Figure 7. PRO 2000 binds the gp140CN54 coreceptor binding site and protects against vaginal lavage-mediated degradation. (A)
gp140CN54 and the control protein BSA were immobilized on a CM5 sensor chip and 100 mM PRO 2000 was flowed over the chip. The mean curve
(solid line) 6 SD (dashed line) of three independent experiments is shown. (B) Competition of PRO 2000 with mAb-binding (mAbs used at 50%
binding concentration) was determined by ELISA using immobilized gp140CN54; Means of triplicates 6 SD are shown. (C) Western blot of gp140CN54
in human vaginal lavage incubated either alone or in the presence of 100 mM PRO 2000 at 37uC for the indicated periods of time. Uncleaved gp140
shows an apparent mol wt of 160 kDa. (D) Quantification of four independent stability experiments 6 SD. *p,0.05.
doi:10.1371/journal.pone.0015861.g007
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was determined in duplicate in at least two independent assays.
Stability of gp140 in human vaginal lavage (HVL)
HVL was collected with a sterile pipette, diluted 1:1 in H2O and
was stored at 280uC after insoluble components were removed by
centrifugation. For the stability assay, 0.5 mg gp140CN54 was
incubated in HVL in the presence or absence of 100 mM PRO
2000 at 37uC and stored at 280uC until analyzed. Samples were
subjected to SDS-PAGE and analyzed by Western blotting.
Sample preparation and ELISA
Vaginal lavage and serum samples were cleared by centrifuga-
tion at 20,0006 ga t4 uC and stored at 220uC until analyzed.
Antigen-specific and total antibody levels were determined by
ELISA. High protein binding ELISA plates were coated with
gp140CN54 in PBS, blocked with 2% skimmed milk powder in
washing buffer (WB, 0.05% Tween-20 in PBS) for mouse
experiments, 2% BSA in WB for rabbit IgG, 10% goat serum in
WB for rabbit IgA and incubated with serial dilutions of samples.
For rabbit total IgG and IgA assays, plates were coated with
capture antibody (Serotec 403001, Abcam ab2758, respectively)
and blocked with 10% goat serum in WB. Bound antibodies were
detected with the appropriate secondary reagents: anti-mouse
IgG-HRP (STAR120P, Serotec, Oxford, UK); anti-mouse IgA
(STAR85, Serotec) conjugated to biotin; anti-mouse IgG1-HRP
and IgG2a-HRP (BD Biosciences, Oxford, UK); anti-rabbit IgG-
HRP (Sigma-Aldrich); anti-rabbit IgA (A120-109A, Bethyl,
Montgomery, TX) conjugated to biotin; TMB substrate (Thermo
Fisher Scientific, Rockford, IL); and OD values were read at
450 nm.
Competition ELISA was performed using immobilized
gp140CN54 and binding of epitope-defined human mAbs was
detected using HRP-conjugated goat anti-human IgG Fcc. mAb
specific for the CD4-induced site were co-incubated with 2 mg/ml
sCD4.
ELISA data were analyzed by subtracting the plate background
from all readings and by fitting a sigmoidal dose response curve to
the data for each sample by using the Prism software (Graphpad,
San Diego, CA). The endpoint titre was determined from the
maximum dilution of sample at which the OD450 signal was
greater than the threshold (0.01), which was always greater than
two standard deviations above background.
Culture of inguinal lymph node cells and cytokine assay
One week prior to the isolation of cells, all mice described in
Figure 3A–C received a final vaginal immunization with the same
formulations as before. Cells derived from the vagina draining
inguinal lymph nodes of these mice were isolated and culfotured
for three days in the presence or absence of 15 mg/mL gp140.
Cytokine profiling was done by Bio-Plex cytokine assay (Bio-Rad,
Hercules, CA) according to the manufacturers instructions.
TLR reporter cell assay
Immortalized mouse embryonic fibroblasts (C3H/WT MEF,
Invivogen, San Diego, CA) were used as TLR-reporter cell line.
Briefly, cells were seeded on day 0 at 1610
4 per well in 96-well
plates and cultured overnight. On day 1, 130 mL medium was
replaced with medium containing the appropriate concentrations
of TLR-agonist (Invivogen) and/or PRO 2000. On day 2, 20 mL
of culture supernatant was removed and the phosphatase content
was quantified by colorimetric substrate reaction (P5994, Sigma-
Aldrich).
Surface plasmon resonance (SPR)
SPR analysis was performed on a BIAcore 2000 biosensor (GE-
Healthcare) by coupling gp140IIIB and gp140CN54 to a CM5
sensor chip to produce 11000-12000 RU. The antigenicity of
gp140 was analyzed using different HIV-1 Env-specific mAbs
(50 mg/mL), sCD4 (25 mg/mL) or combinations thereof. Recom-
binant human TLR4-MD2 complexes (R&D Systems, Minneap-
olis, MN) were immobilized on a CM5 sensor chip at
approximately 8000 RU. The immobilization of lipid A (Sigma-
Aldrich) onto the HPA biosensor chip was carried out as described
previously [55]. Samples were injected for 2 min at a flow rate of
20 mL/min.
Total Ig determination by multiplex immunoassay
The total IgG and IgA concentration of mouse vaginal lavage
was determined using a multiplex mouse immunoglobulin
isotyping kit (Millipore, Billerica, MA) following the manufactur-
er’s instructions. Assays were read on a Bio-Plex system (Bio-Rad).
Total IgG and IgA concentrations in mg/ml were used to
normalize mucosal IgG and IgA endpoint titres.
Blue native PAGE
Blue native PAGE was performed essentially as described
elsewhere [56]. Briefly, proteins were diluted in 50 mM Bis-Tris
buffer pH 7.0 and were separated on 3-12% Bis-Tris gels
(Invitrogen, Paisley, UK) in the presence of a final concentration
of 0.05% Triton x-100. After electrophoresis, gels were silver-
stained to visualize less abundant protein fractions.
Statistical analysis
Endpoint titres were log-transformed and analyzed using a
Kolmogorov-Smirnov normality test. If the data showed a normal
distribution within each compared group an unpaired t-test with a
confidence interval of 95% was used to assess for statistical
significance defined as p,0.05. If the data were not normally
distributed, they were analyzed using a Mann-Whitney test with
the same confidence interval and significance limit. For antibody
titres, results are presented as geometric group means or were log-
transformed and presented as means 6 SEM; all other data are
presented as means 6 SD.
Supporting Information
Figure S1 Biochemical characterization of the immu-
nogen. (A) Antigenic analysis of HIV-1 gp140CN54 compared to
HIV-1 IIIB gp140 using a panel of epitope-defined mAbs and
soluble CD4. The relative binding of the analytes in a surface
plasmon resonance based binding assay is given in response unit
(RU)-ranges: - = 0-150RU; + =151-500 RU; ++ =501-1500
RU; +++ = above 1501 RU. Means of two independent
experiments are shown (B) Blue native PAGE analysis of the
antigen. gp140CN54 shows an apparent native molecular weight of
approximately 480 kDa.
(TIF)
Figure S2 Total Immunoglobulin content of vaginal
lavage samples and correlation of rabbit antigen-
specific vaginal- and serum IgG. Total rabbit IgA (A) and
IgG (B) content of vaginal lavage samples and Pearson correlation
(C) of week 11 rabbit vaginal and serum IgG responses from the
experiment depicted in Figure 2.
(TIF)
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